NEW YORK, NY / ACCESSWIRE / October 11, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ANVS Shareholders Click Here: https://www.zlk.com/pslra-1/annovis-bio-inc-loss-submission-form?prid=20309&wire=1
SAVA Shareholders Click Here: https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20309&wire=1
WDH Shareholders Click Here: https://www.zlk.com/pslra-1/waterdrop-inc-loss-submission-form?prid=20309&wire=1

* ADDITIONAL INFORMATION BELOW *

Annovis Bio, Inc. (NYSE American:ANVS)
ANVS Lawsuit on behalf of: investors who purchased May 21, 2021 - July 28, 2021
Lead Plaintiff Deadline: October 18, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/annovis-bio-inc-loss-submission-form?prid=20309&wire=1
According to the filed complaint, during the class period, Annovis Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Annovis's ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgment, and problem solving; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Cassava Sciences, Inc. (NASDAQ:SAVA)
SAVA Lawsuit on behalf of: investors who purchased September 14, 2020 - August 27, 2021
Lead Plaintiff Deadline: October 26, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20309&wire=1
According to the filed complaint, during the class period, Cassava Sciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.

Waterdrop Inc. (NYSE:WDH)
This lawsuit is on behalf of all persons or entities who purchased Waterdrop American Depositary Shares in or traceable to the Company's May 2021 initial public offering.
Lead Plaintiff Deadline: November 15, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/waterdrop-inc-loss-submission-form?prid=20309&wire=1
According to the filed complaint, (a) Waterdrop had achieved a substantial portion of its historical revenue growth through illicit means that ran afoul of Chinese rules and regulations governing the insurance industry; (b) Waterdrop had been ordered by the Chinese government to shut down its mutual aid platform because of its failure to comply with Chinese law; (c) Waterdrop was under investigation by regulatory authorities for continued violations of Chinese law; (d) as a result of (a)-(c) above, there existed a material undisclosed risk and substantial likelihood that Waterdrop would face severe adverse actions by regulatory authorities following the IPO; (e) Waterdrop's operating losses had increased more than four-fold in the first quarter of 2021 as a result of the cessation of its mutual aid business and rapidly growing customer acquisition costs; and (f) as a result of (a)-(e) above, the Registration Statement's representations regarding Waterdrop's historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of the Company in the lead up to the IPO, were materially false and misleading, and lacked a factual basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

CONTACT: Levi & Korsinsky, LLP